ArticleAmerican journal of cancer research2026
Low dose abemaciclib in heavily treated hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Yi-Ru Lu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.